Daniel S. Pereira, PhD, currently serves as Chief Scientific Officer at Invenra. He brings more than 20 years of experience in oncology biologics drug discovery and development in biotech and pharma as a scientific leader, strategist, innovator, collaborator and fundraiser. His career efforts have led to the discovery and development of a range of FDA-approved drugs for patients with cancer.
Prior to joining Invenra, Dan was Chief Scientific Officer at Arch Oncology developing differentiated CD47 axis agents; Vice President, Discovery Research at Astellas/Agensys progressing novel antibody drug conjugates and bispecific antibodies; Vice President, Research at Roche/Arius advancing FunctionFIRST antibodies and Director, Tumor Biology at ImClone Systems Inc. developing antibodies to receptor tyrosine kinases.
Dan received his BS and MS degrees from the University of Manitoba and his PhD from McMaster University in Dr. Frank Graham’s lab studying adenoviral transformation. His postdoctoral training in the lab of Dr. John Dick at the University of Toronto focused on leukemogenesis of cancer stem cells. Dan has also been an author on >100 manuscripts, abstracts and patents collectively.
